

THRU ONLINE FILING

June 24, 2020

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Dear Sir,

This is further to our letter dated 21st March, 2020 informing you about USFDA exemption from import alert for APIs Chloroquine Phosphate and Hydroxychloroquine Sulfate manufactured from Company's APIs manufacturing facility situated at Ratlam (M.P).


We now wish to inform you that the US FDA vide its email dated 23rd June 2020 has communicated to the Company that shortage implications for Chloroquine Phosphate API has changed and Chloroquine Phosphate drug product is no longer in shortage and therefore, no shipment of API Chloroquine Phosphate will be excluded from the import alert.

USFDA has also informed that due to potential shortage implications and/or medical necessity, exception to the import alert has been made for API Hydroxychloroquine Sulfate. US FDA has further informed that this exception will be re-considered if the shortage implications change.

This is for your information and record.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.
www.ipca.com